David Lebovitz

Stock Analyst at Citigroup

(3.39)
# 1,008
Out of 5,045 analysts
91
Total ratings
68.18%
Success rate
10.58%
Average return

Stocks Rated by David Lebovitz

Alnylam Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $527$583
Current: $454.30
Upside: +28.33%
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82$78
Current: $52.23
Upside: +49.34%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378$469
Current: $421.18
Upside: +11.35%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70$74
Current: $42.99
Upside: +72.13%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37$38
Current: $72.19
Upside: -47.36%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29$17
Current: $68.14
Upside: -75.05%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57$54
Current: $110.00
Upside: -50.91%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38$35
Current: $75.09
Upside: -53.39%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16$17
Current: $1.63
Upside: +942.94%
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12$11
Current: $1.68
Upside: +556.72%
Maintains: Overweight
Price Target: $194$199
Current: $201.95
Upside: -1.46%
Maintains: Overweight
Price Target: $510$480
Current: $5.81
Upside: +8,161.62%